Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H44O3 |
Molecular Weight | 416.6365 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C)[C@H](C)CCCC(C)(C)O
InChI
InChIKey=GMRQFYUYWCNGIN-NKMMMXOESA-N
InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/1998/21068lbl.pdfhttps://www.ncbi.nlm.nih.gov/mesh/68002117 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/021068a_phrmr_P1.pdfCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/cdi/calcitriol.html
http://www.wikidoc.org/index.php/Calcitriol_(oral)
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/1998/21068lbl.pdfhttps://www.ncbi.nlm.nih.gov/mesh/68002117 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/021068a_phrmr_P1.pdf
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/cdi/calcitriol.html
http://www.wikidoc.org/index.php/Calcitriol_(oral)
Trans-calcitriol or Calcitriol Impurity A, is the impurity of Calcitriol. Calcitriol is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR). Calcitriol Impurity A is the physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4313704
Curator's Comment: First obtained from chick intestine and designated as metabolite 4B
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P11473 Gene ID: 7421.0 Gene Symbol: VDR Target Organism: Homo sapiens (Human) |
0.22 nM [Kd] | ||
Target ID: CHEMBL340 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ROCALTROL Approved UsePredialysis Patients Calcitriol Capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol Capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol Capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. Launch Date1978 |
|||
Preventing | ROCALTROL Approved UsePredialysis Patients Calcitriol Capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol Capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol Capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. Launch Date1978 |
|||
Primary | VECTICAL Approved UseVECTICAL Ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in adults 18 years and older. Launch Date1978 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1100 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12496746 |
38 μg 3 times / week multiple, oral dose: 38 μg route of administration: Oral experiment type: MULTIPLE co-administered: PACLITAXEL |
CALCITRIOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
73.1799999999999 pg/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00419666 |
3 ug/g 2 times / day multiple, topical dose: 3 ug/g route of administration: topical experiment type: multiple co-administered: |
CALCITRIOL plasma | Homo sapiens population: unhealthy age: Adolescents sex: F+M food status: |
|
75.74 pg/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00419666 |
3 ug/g single, topical dose: 3 ug/g route of administration: topical experiment type: single co-administered: |
CALCITRIOL plasma | Homo sapiens population: unhealthy age: Adolescents sex: F+M food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8100 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12496746 |
38 μg 3 times / week multiple, oral dose: 38 μg route of administration: Oral experiment type: MULTIPLE co-administered: PACLITAXEL |
CALCITRIOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
737.74 pg*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00419666 |
3 ug/g 2 times / day multiple, topical dose: 3 ug/g route of administration: topical experiment type: multiple co-administered: |
CALCITRIOL plasma | Homo sapiens population: unhealthy age: Adolescents sex: F+M food status: |
|
764.74 pg*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00419666 |
3 ug/g single, topical dose: 3 ug/g route of administration: topical experiment type: single co-administered: |
CALCITRIOL plasma | Homo sapiens population: unhealthy age: Adolescents sex: F+M food status: |
|
549.29 pg*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00419666 |
3 ug/g 2 times / day multiple, topical dose: 3 ug/g route of administration: topical experiment type: multiple co-administered: |
CALCITRIOL plasma | Homo sapiens population: unhealthy age: Adolescents sex: F+M food status: |
|
575.12 pg*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00419666 |
3 ug/g single, topical dose: 3 ug/g route of administration: topical experiment type: single co-administered: |
CALCITRIOL plasma | Homo sapiens population: unhealthy age: Adolescents sex: F+M food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
25 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12496746 |
38 μg 3 times / week multiple, oral dose: 38 μg route of administration: Oral experiment type: MULTIPLE co-administered: PACLITAXEL |
CALCITRIOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. | 2000 Jul |
|
24,25-dihydroxyvitamin D3 in combination with 1,25-dihydroxyvitamin D3 ameliorates renal osteodystrophy in rats with chronic renal failure. | 2000 May |
|
Beneficial effect of 1,25 dihydroxyvitamin D3 on cytokine-treated human pancreatic islets. | 2001 Apr |
|
Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. | 2001 Dec |
|
The anti-proliferative effect of calcitriol on HL-60 cells is neutralized by uraemic biological fluids. | 2001 Feb |
|
1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. | 2001 Jan |
|
Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. | 2001 Jun 15 |
|
Dietary phosphorus deprivation induces 25-hydroxyvitamin D(3) 1alpha-hydroxylase gene expression. | 2001 May |
|
Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. | 2002 Feb |
|
Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. | 2002 Jul |
|
Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. | 2002 Nov 1 |
|
Differentiation of murine melanocyte precursors induced by 1,25-dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. | 2002 Sep |
|
Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. | 2002 Sep 1 |
|
9-cis retinoic acid accelerates calcitriol-induced osteocalcin production and promotes degradation of both vitamin D receptor and retinoid X receptor in human osteoblastic cells. | 2003 Aug 15 |
|
Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells. | 2003 May |
|
Previtamin D3 with a trans-fused decalin CD-ring has pronounced genomic activity. | 2003 Sep 12 |
|
DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. | 2004 Apr 13 |
|
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. | 2004 Mar |
|
1,25(OH)2D3 inhibits bone marrow adipogenesis in senescence accelerated mice (SAM-P/6) by decreasing the expression of peroxisome proliferator-activated receptor gamma 2 (PPARgamma2). | 2004 Mar |
|
Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels. | 2005 Apr |
|
Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism. | 2005 Apr |
|
Human bladder as a novel target for vitamin D receptor ligands. | 2005 Feb |
|
Amphiregulin is a novel growth factor involved in normal bone development and in the cellular response to parathyroid hormone stimulation. | 2005 Feb 4 |
|
Regulation of the human vitamin D3 receptor promoter in breast cancer cells is mediated through Sp1 sites. | 2005 Jan 31 |
|
Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. | 2005 Jun |
|
Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats. | 2005 Mar |
|
Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. | 2005 Mar |
|
Regulation of renal calcium receptor gene expression by 1,25-dihydroxyvitamin D3 in genetic hypercalciuric stone-forming rats. | 2005 May |
|
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. | 2005 Sep 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: The recommended initial dose of Calcitriol Injection, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered intravenously three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose.
Apply Calcitriol Ointment to affected areas twice daily, morning and evening. The maximum weekly dose should not exceed 200 grams. Calcitriol Ointment is not for oral, ophthalmic or intravaginal use.
Calcitriol can be administered orally either as a capsule (0.25 mcg or 0.50 mcg) or as an oral solution (1 mcg/mL).
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17965521
CYP3A4 mRNA expression in LS180 cells treated with 100 nM of Calcitriol for 6 and 24 h was approximately 80- and 500-fold higher than the control.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000006996
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
WHO-VATC |
QD05AX03
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
NCI_THESAURUS |
C39713
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
LOINC |
1649-3
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
LIVERTOX |
140
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
NDF-RT |
N0000006996
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
WHO-ATC |
A11CC04
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
NDF-RT |
N0000006996
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
NDF-RT |
N0000006996
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
LOINC |
14566-4
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
NDF-RT |
N0000175908
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
WHO-VATC |
QA11CC04
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
WHO-ATC |
D05AX03
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
||
|
NCI_THESAURUS |
C1934
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2779
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
250-963-8
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
5280453
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
100000092790
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
CALCITRIOL
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
17823
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
m2917
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB00136
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
1086301
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
D002117
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
DTXSID5022722
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
4393
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
CHEMBL846
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
FXC9231JVH
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
466
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
C330
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
3482
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
SUB06047MIG
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
1894
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | RxNorm | ||
|
FXC9231JVH
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
Calcitriol
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY | |||
|
32222-06-3
Created by
admin on Fri Dec 15 15:48:11 GMT 2023 , Edited by admin on Fri Dec 15 15:48:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE INACTIVE (PARENT)
PARENT (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)